Quaovi Sodji

Dr. Quaovi Sodji

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2016 in Science
Verified
Journal Article
Closed access
PDF file
ERErinn Rankin
Erinn Rankin
QSQuaovi Sodji
Quaovi Sodji
Metastatic disease is the leading cause of cancer-related deaths and involves critical interactions between tumor cells and the microenvironment. Hypoxia is a potent microenvironmental factor promoting metastatic progression. Clinically, hypoxia and the expression of the hypoxia-inducible transcription factors HIF-1 and HIF-2 are associated with increased distant metastasis and poor survival in a variety of tumor types. Moreover, HIF signaling in malignant cells influences multiple steps within the metastatic cascade. Here we review research focused on elucidating the mechanisms by which the hypoxic tumor microenvironment promotes metastatic progression. These studies have identified potential biomarkers and therapeutic targets regulated by hypoxia that could be incorporated into strategies aimed at preventing and treating metastatic disease.

1 January 2009 in Cancer Cell
Verified
Journal Article
Closed access
JEJanine Terra Erler
Janine Terra Erler
KBKevin L. Bennewith
Kevin L. Bennewith
TCThomas R. Cox
Thomas R. Cox
GLGeorgina Lang
Georgina Lang
DBDemelza Bird
Demelza Bird
QSQuaovi Sodji
Quaovi Sodji

15 February 2008 in Cell Death & Differentiation
Verified
Journal Article
Closed access
PDF file
ERErinn Rankin
Erinn Rankin
QSQuaovi Sodji
Quaovi Sodji

1 September 2009 in Molecular Cell
Verified
Journal Article
Closed access
XHXin Huang
Xin Huang
LDLianghao Ding
Lianghao Ding
KBKevin L. Bennewith
Kevin L. Bennewith
RTRicky T. Tong
Ricky T. Tong
SWScott M Welford
Scott M Welford
QSQuaovi Sodji
Quaovi Sodji

3 August 2011 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
DCDenise A. Chan
Denise A. Chan
PSPatrick D. Sutphin
Patrick D. Sutphin
PNPhuong Nguyen
Phuong Nguyen
STSandra Turcotte
Sandra Turcotte
ELEdwin W. Lai
Edwin W. Lai
QSQuaovi Sodji
Quaovi Sodji
Identifying new targeted therapies that kill tumor cells while sparing normal tissue is a major challenge of cancer research. Using a high-throughput chemical synthetic lethal screen, we sought to identify compounds that exploit the loss of the von Hippel–Lindau (VHL) tumor suppressor gene, which occurs in about 80% of renal cell carcinomas (RCCs). RCCs, like many other cancers, are dependent on aerobic glycolysis for ATP production, a phenomenon known as the Warburg effect. The dependence of RCCs on glycolysis is in part a result of induction of glucose transporter 1 (GLUT1). Here, we report the identification of a class of compounds, the 3-series, exemplified by STF-31, which selectively kills RCCs by specifically targeting glucose uptake through GLUT1 and exploiting the unique dependence of these cells on GLUT1 for survival. Treatment with these agents inhibits the growth of RCCs by binding GLUT1 directly and impeding glucose uptake in vivo without toxicity to normal tissue. Activity of STF-31 in these experimental renal tumors can be monitored by [18F]fluorodeoxyglucose uptake by micro–positron emission tomography imaging, and therefore, these agents may be readily tested clinically in human tumors. Our results show that the Warburg effect confers distinct characteristics on tumor cells that can be selectively targeted for therapy.

30 March 2016 in Nature Cell Biology
Verified
Journal Article
Closed access
PDF file
ELEdward L. LaGory
Edward L. LaGory
QSQuaovi Sodji
Quaovi Sodji